FDA Inspection 1076633 — Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.
The FDA completed an inspection of Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. on December 7, 2018 in Singapore. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 7, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Singapore (Singapore)